A growing number of Americans are experiencing a reduction in insurance coverage for popular weight loss medications such as Zepbound and Wegovy. This trend is resulting in increased premiums and substantial out-of-pocket expenses for patients.

Coverage Changes and Rising Costs

Meghan Lena, a special education teacher from Massachusetts, encountered repeated changes to her prescription drug benefits for obesity medications. Initially, her Zepbound prescription was covered with a $30 monthly copay, which helped her lose 50 pounds and improve her overall health.

Insurance Provider Shifts

Lena’s insurance provider, CVS Caremark, first shifted its preference to Novo Nordisk’s Wegovy, and then eliminated coverage for Wegovy altogether within months. Simultaneously, her monthly health insurance premium increased by 20%, directly linked to the rising costs of GLP-1 drugs like Wegovy and Zepbound.

Lena expressed frustration, feeling that the insurance company was making medical decisions instead of her doctor. This led to feelings of anger and helplessness.

Widespread Trend of Diminishing Coverage

Research from GoodRx confirms a widespread trend of decreasing coverage for these medications. The data indicates that an estimated 12 million individuals will lose coverage for both Zepbound and Wegovy between 2025 and 2026.

Restrictions and Out-of-Pocket Expenses

Even those who maintain some coverage often face restrictions, including prior authorization requirements and BMI thresholds. Many insured individuals still encounter significant out-of-pocket costs, as plans frequently cover only a small portion of the drug’s price.

The Obesity Action Coalition highlights the arbitrary nature of insurance policies, noting that carriers are implementing limitations and restrictions to reduce the number of eligible patients.

Impact on Patients and Healthcare Professionals

While employer coverage for GLP-1 drugs has seen a slight increase, the number of employers *not* offering such coverage has also risen. This creates a complex situation for patients seeking access to these medications.

Burden on Healthcare Providers

Dr. Varney, an obesity medicine director at UVA Health, reports that approximately 60% of her patients now pay out of pocket for their medications. She dedicates a significant amount of time to calculating costs and identifying affordable options.

PBMs Respond

Pharmaceutical benefit managers (PBMs) defend their formulary strategies, stating they leverage competition to lower costs and ensure clinically appropriate coverage. CVS Caremark specifically attributes the primary barrier to patient access to the high list prices set by drug manufacturers.

Seeking Alternative Solutions

Individuals like Meghan Lena are exploring alternative solutions, such as compounded medications prescribed by their doctors. These medications bypass the traditional FDA approval process and may offer a more affordable, though less regulated, option. This situation highlights growing concerns about access to essential medications and the increasing influence of insurance companies in medical decision-making.